Promising methodological approaches to preclinical studies of biomedical cell-based products and their possible quality characteristics

Abstract

The analysis of patent and scientific literature on the production of biomedical cell-based products (BMCP) showed that the main patentable developments in this sphere are focused on organ and tissue recovery, preventing transplant rejection and characterization of cell line viability. The researchers have revealed recent tendency for replacing the clinical use of BMCP based on unmodified cells and human cell lines by their genetically modified derivatives. Several dozens of Western companies are the principal developers, holding key patents in this field. At the same time, the analysis of patent activity showed that the technology of BmCp reached its peak of the development in 2000-2010, but many issues related to their safety clinical practice has not been solved yet. The examples of the mentioned issues are low efficiency of implanted cell differentiation maintanance; the possibility of BMCP contamination with infectious agents; nonspecific immunosuppressive effect on recipient organism; poor control of gene expression in transplant cell lines differentiated in a target organ and some

Keywords

• биомедицинский клеточный продукт
• биомедицинские клеточные технологии
• стволовые клетки
• клеточные линии
• мультипотентные мезенхимальные стромальные клетки
• эмбриональные стволовые клетки
• адипоциты
• остеобласты
• миоциты
• бмкп